February 10, 2026 Fourth Quarter & Full Year 2025 Earnings Presentation Disclaimer Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "anticipate", "believe", "continue", "could", "estimate", "expect", "hope", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "should", "strive", "seeks", "plans", "would", "will", "understand" and similar words are i ...

Financial Performance - Mirion's Q1 2025 revenue reached $202 million, reflecting a 49% total increase and a 60% organic growth compared to Q1 2024[10, 19] - Adjusted EBITDA for Q1 2025 was $467 million, an 182% increase from Q1 2024, with a margin expansion of 260 bps[9, 10] - Adjusted EPS increased by 667% to $010 in Q1 2025 from $006 in Q1 2024[22] - Adjusted Free Cash Flow for Q1 2025 was $29 million, a significant improvement compared to previous years[9, 39] Orders and Backlog - Strong Q1 orders with an 115% increase compared to Q1 2024, indicating consistent demand[9, 10] - The company repurchased 116 million shares in Q1 2025 as part of its capital deployment strategy[11] - Backlog trend shows a slight decrease of 1% vs adjusted Q1 2024, reaching $814 million in Q1 2025[48] Segment Performance - Nuclear & Safety segment revenue grew by 60% in Q1 2025, with organic growth of 76%[25] - Medical segment revenue increased by 27% in Q1 2025, with organic growth of 30%[32] Guidance and Outlook - The company reaffirms its 2025 guidance for Organic Revenue Growth (55% - 75%), Adjusted EBITDA ($215 - $230 million), Adjusted FCF, and Adjusted EPS[41]